Want to join the conversation?
$JNJ General Update: Janssen Biotech, Inc announced the opening of a daratumumab expanded access program (EAP) for eligible US patients. Daratumumab is an investigational human anti-CD38 monoclonal antibody being evaluated in clinical trials as a treatment for people with multiple myeloma.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.